Ford CL, Riggs WJ, Quigley T, et al. The natural history, clinical outcomes, and genotype-phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review. Hum Genet. 2023;142(10):1429–49.

Article  PubMed  PubMed Central  Google Scholar 

Moser T, Starr A. Auditory neuropathy—neural and synaptic mechanisms. Nat Rev Neurol. 2016;12(3):135–49.

Article  CAS  PubMed  Google Scholar 

Lustig L, Bance M, Ishiyama A, et al. Intracochlear administration of DBOTO gene therapy in pediatric patients with profound hearing loss due to otoferlin mutations: the CHORD phase 1/2 open-label trial [abstract no. 10]. Mol Ther. 2024;32(4 Suppl. 1):6.

Chung Y, Koehler SD, Cancelarich S, et al. Functional, sustained recovery of hearing in otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Mol Ther Methods Clin Dev. 2025;33(4):1–18.

Article  Google Scholar 

Qi J, Xu L, Zeng FG, et al. OTOF-related gene therapy: a new way but a long road ahead. Lancet. 2025;405(10481):777–9.

Article  PubMed  Google Scholar 

Decibel Therapeutics. Decibel Therapeutics receives FDA clearance of IND application for DB-OTO, a gene therapy product candidate designed to provide hearing to individuals with otoferlin-related hearing loss [media release]. 17 Oct 2022. https://www.biospace.com/.

Decibel Therapeutics. Decibel Therapeutics announces exclusive licensing agreements for hearing loss gene therapy technology [media release]. 2 Nov 2020. https://www.biospace.com/.

Akil O, Dyka F, Calvet C, et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci USA. 2019;116(10):4496–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Moyed H, Cepeda AP, Jung S, et al. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019. https://doi.org/10.15252/emmm.201809396.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Food & Drug Administration. FDA approves first-ever gene therapy for treatment of genetic hearing loss under national priority voucher program [media release]. 23 Apr 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher.

Regeneron Pharmaceuticals. OTARMENI™ (lunsotogene parvec-cwha) suspension, for intracochlear infusion: US prescribing information. 2026. https://www.regeneron.com/downloads/otarmeni_fpi.pdf. Accessed 30 Jun 2026.

Regeneron Pharmaceuticals. Otarmeni™ (lunsotogene parvec-cwha) approved by FDA as first and only gene therapy for genetic hearing loss; Regeneron to provide Otarmeni for free in the U.S [media release]. 23 Apr 2026. http://www.regeneron.com/.

U.S. Food & Drug Administration. OTARMENI: summary basis for regulatory action. 2026. https://www.fda.gov/vaccines-blood-biologics/otarmeni. Accessed 30 Jun 2026.

Decibel Therapeutics. Decibel Therapeutics receives European Orphan Drug designation for lead gene therapy candidate DB-OTO [media release]. 30 Mar 2023. https://www.biospace.com/.

Regeneron Pharmaceuticals. Regeneron completes acquisition of Decibel Therapeutics, adding promising gene therapy programs for hearing loss [media release]. 25 Sep 2023. http://www.regeneron.com/.

Regeneron Pharmaceuticals, Decibel Therapeutics. Regeneron and Decibel Therapeutics announce strategic collaboration to discover and develop therapeutics for hearing loss and tinnitus [media release]. 29 Nov 2017. http://www.regeneron.com/.

Decibel Therapeutics. Decibel Therapeutics announces extension of research term under strategic collaboration with Regeneron to discover and develop gene therapies for hearing loss [media release]. 22 Nov 2021. https://www.biospace.com/.

U.S. Securities And Exchange Commission. 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1656536/000095017023007849/dbtx-20221231.htm. Accessed 30 Jun 2026.

Decibel Therapeutics. Decibel and Catalent sign development and manufacturing agreement for dual-vector gene therapy for the treatment of congenital hearing loss [media release]. 4 Feb 2021. https://biologics.catalent.com/catalent-news/decibel-and-catalent-sign-development-and-manufacturing-agreement-for-dual-vector-gene-therapy-for-the-treatment-of-congenital-hearing-loss/.

Valayannopoulos V, Bance M, Carvalho DS, et al. DB-OTO gene therapy for inherited deafness. N Engl J Med. 2026;394(11):1074–83.

Article  CAS  PubMed  Google Scholar 

U.S. Food & Drug Administration. OTARMENI: letters, reviews, and related documents. 9. Statistical review. 2026. https://www.fda.gov/vaccines-blood-biologics/otarmeni. Accessed 30 Jun 2026.

U.S. Food & Drug Administration. OTARMENI: letters, reviews, and related documents. 8. Pharmacovigilance original BLA memorandum. 2026. https://www.fda.gov/vaccines-blood-biologics/otarmeni. Accessed 30 Jun 2026.